Draft executive order favors pharma over PBMs, hospitals

A draft executive order aimed at "reducing the cost of medical products and enhancing American biomedical innovation" includes provisions intended to cut PBMs' revenues and to reform the 340B program in ways that would reduce costs to drug companies and reduce discounts available to hospitals. The draft, obtained by BioCentury, does not directly cut or control drug prices, and does not include negotiation of government drug purchases.

Labeled as “internal, deliberative, pre-decisional, confidential,” the draft could be modified before President Trump signs it. The document indicates that it will be signed in June. ...